Yvonne is currently Chief Operating Officer at Alnylam Pharmaceuticals, a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. Yvonne has more than 20 years of global experience in the pharmaceutical industry, spanning research and development, strategy and commercial development. Yvonne serves on the boards of directors of Pacira Pharmaceuticals and Advanced Accelerator Applications. She is also on the advisory board of the Bill and Melinda Gates Foundation.
Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer and a member of the global executive team for the $16 billion Specialty Business with accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience, and rare disease areas. Prior to Pfizer, she was at Glaxo SmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development, serving on the corporate executive investment committee. She was responsible for enabling strategy development and execution to achieve GSK’s goal of delivering five to seven new medicines per year while reducing research and development spend. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicine Development and Chief Medical Officer for Europe.
Yvonne trained as a physician and earned her medical degree from Leeds University in the UK and her M.B.A. from INSEAD, France.
Chair of the Science & Policy Committee
Member of the Audit Committee